Marking the completion of one of European biotech’s major comeback stories in recent years, Newron Pharmaceuticals SpA and its partner Zambon SpA submitted a marketing authorization application (MAA) for safinamide in Parkinson’s disease to the European Medicines Agency and are on track for a potential approval during 2014.